16-172950-C-A
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 3 ACMG points: 4P and 1B. PP3_StrongBP6
The NM_000517.6(HBA2):c.38C>A(p.Ala13Asp) variant causes a missense change involving the alteration of a non-conserved nucleotide. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another nucleotide change resulting in the same amino acid substitution has been previously reported as Likely benign in UniProt.
Frequency
Genomes: not found (cov: 1)
Exomes 𝑓: 0.000019 ( 1 hom. )
Consequence
HBA2
NM_000517.6 missense
NM_000517.6 missense
Scores
4
4
7
Clinical Significance
Conservation
PhyloP100: 0.164
Genes affected
HBA2 (HGNC:4824): (hemoglobin subunit alpha 2) The human alpha globin gene cluster located on chromosome 16 spans about 30 kb and includes seven loci: 5'- zeta - pseudozeta - mu - pseudoalpha-1 - alpha-2 - alpha-1 - theta - 3'. The alpha-2 (HBA2) and alpha-1 (HBA1) coding sequences are identical. These genes differ slightly over the 5' untranslated regions and the introns, but they differ significantly over the 3' untranslated regions. Two alpha chains plus two beta chains constitute HbA, which in normal adult life comprises about 97% of the total hemoglobin; alpha chains combine with delta chains to constitute HbA-2, which with HbF (fetal hemoglobin) makes up the remaining 3% of adult hemoglobin. Alpha thalassemias result from deletions of each of the alpha genes as well as deletions of both HBA2 and HBA1; some nondeletion alpha thalassemias have also been reported. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 3 ACMG points.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.975
BP6
Variant 16-172950-C-A is Benign according to our data. Variant chr16-172950-C-A is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 993109.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=1, Uncertain_significance=1}.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
HBA2 | ENST00000251595.11 | c.38C>A | p.Ala13Asp | missense_variant | Exon 1 of 3 | 1 | NM_000517.6 | ENSP00000251595.6 | ||
HBA2 | ENST00000484216.1 | c.5C>A | p.Ala2Asp | missense_variant | Exon 1 of 2 | 1 | ENSP00000495899.1 | |||
HBA2 | ENST00000482565.1 | n.57C>A | non_coding_transcript_exon_variant | Exon 1 of 2 | 1 | |||||
HBA2 | ENST00000397806 | c.-10C>A | 5_prime_UTR_variant | Exon 1 of 3 | 2 | ENSP00000380908.1 |
Frequencies
GnomAD3 genomes Cov.: 1
GnomAD3 genomes
Cov.:
1
GnomAD4 exome AF: 0.0000190 AC: 7AN: 368084Hom.: 1 Cov.: 0 AF XY: 0.0000310 AC XY: 6AN XY: 193584
GnomAD4 exome
AF:
AC:
7
AN:
368084
Hom.:
Cov.:
0
AF XY:
AC XY:
6
AN XY:
193584
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 1
GnomAD4 genome
Cov.:
1
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:1Benign:1
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not provided Uncertain:1Benign:1
Likely benign, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Apr 10, 2024 | The Hb-J-Paris-I variant (HBA2: c.38C>A; p.Ala13Asp, also known as Ala12Asp when numbered from the mature protein, rs281864809, HbVar ID: 15) is reported in the literature in individuals with no clinical symptoms or hematological alterations, and is described as a stable hemoglobin variant (see link to HbVar and references therein, de la Fuente-Gonzalo 2019, Kimura 2015, Molchanova 1994). This variant is absent from the Genome Aggregation Database, indicating it is not a common polymorphism. The alanine at codon 13 is weakly conserved, and computational analyses are uncertain whether this variant is neutral or deleterious (REVEL: 0.558). Based on available information, this variant is considered to be likely benign. References: Link to HbVar: https://globin.bx.psu.edu/hbvar/menu.html de la Fuente-Gonzalo F et al. Characterization of deletional and non-deletional alpha globin variants in a large cohort from Spain between 2009 and 2014. Ann Hematol. 2019 Jul;98(7):1537-1545. PMID: 31025160. Kimura EM et al. Investigating alpha-globin structural variants: a retrospective review of 135,000 Brazilian individuals. Rev Bras Hematol Hemoter. 2015 Mar-Apr;37(2):103-8. PMID: 25818820. Molchanova TP et al. The differences in quantities of alpha 2- and alpha 1-globin gene variants in heterozygotes. Br J Haematol. 1994 Oct;88(2):300-6. PMID: 7803274. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Sep 05, 2024 | The HBA2 c.38C>A (p.Ala13Asp) variant has been reported in the published literature in individuals with hematological indices and clinical phenotypes within normal range (PMID: 32597250 (2020), 31025160 (2019), 30489691 (2018), 27387985 (2017), 25818820 (2015), and 119167 (1979)). In an online hemoglobin database, this variant is reported as stable (HbVar (http://globin.cse.psu.edu/cgi-bin/hbvar/counter)). This variant has not been reported in large, multi-ethnic general populations (Genome Aggregation Database, http://gnomad.broadinstitute.org). Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded conflicting predictions that this variant is deleterious or benign. Based on the available information, we are unable to determine the clinical significance of this variant. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Benign
DANN
Benign
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
N
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D
MetaSVM
Uncertain
T
PrimateAI
Uncertain
T
PROVEAN
Benign
N
REVEL
Uncertain
Sift
Uncertain
D
Sift4G
Benign
T
Vest4
MutPred
Loss of MoRF binding (P = 0.0276);
MVP
MPC
ClinPred
T
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at